A Targetable Developmental Program Coregulates Angiogenesis and Immune Evasion in Melanoma

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Ultraviolet radiation induces DNA mutations in melanoma, creating neoantigens that can stimulate anti-tumor immunity.
• Melanoma cells evade immune detection through epigenetic changes and by interacting with their microenvironment.
• Solid tumors often exhibit increased vascularization that paradoxically limits immune cell infiltration.

Purpose of the Study:

• To investigate the role of transcription factors in melanoma progression and immune evasion.
• To identify specific molecular mechanisms driving angiogenesis and immune suppression in melanoma.
• To explore potential therapeutic targets based on identified molecular pathways.

Main Methods:

• Comparative analysis of transcription factor expression in melanoma, naevi, and other cancers.
• Transcriptomic analysis and 3D chromatin profiling.
• In vivo melanoma models to assess HOXD13 function and therapeutic interventions.

Main Results:

• HOXD13, a homeodomain transcription factor, drives a melanoblast-like program in melanoma, correlating with angiogenesis and immune exclusion.
• HOXD13 promotes tumor growth by enhancing angiogenesis and suppressing T-cell infiltration.
• HOXD13 activates VEGFA, SEMA3A, and CD73 via 3D enhancer-promoter interactions, leading to vascular remodeling and adenosine-mediated immunosuppression.

Conclusions:

• HOXD13 plays a critical role in melanoma pathogenesis by orchestrating a dual pro-angiogenic and immunosuppressive axis.
• Combined inhibition of Vascular Endothelial Growth Factor Receptor (VEGFR) and adenosine receptors (AdR) effectively reverses HOXD13-induced tumor growth.
• Targeting the HOXD13 pathway presents a promising therapeutic strategy for cutaneous melanoma.